Treatment of chronic hepatitis C with protease inhibitor-based therapy after liver transplantation

Authors


  • Potential conflict of interest: Dr. Reddy has served on the advisory boards of Merck, Genentech-Roche, Gilead, Vertex, Janssen, Bristol-Myers Squibb, and Idenix and has served as an investigator for Merck, Genentech-Roche, Gilead, Vertex, Janssen, Bristol-Myers Squibb, and AbbVie.

Address reprint requests to: K. Rajender Reddy, M.D., Division of Gastroenterology and Hepatology, Hospital of the University of Pennsylvania, 3400 Spruce Street, 2 Dulles, Philadelphia, PA 19104. E-mail: rajender.reddy@uphs.upenn.edu; fax: 215-662-4835.

Ancillary